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Abstract
Background: Axial spondyloarthropathy typically has its onset in early adulthood and can impact significantly on quality
of life. In the UK, biologic anti-tumour necrosis factor therapy is recommended for patients who are unresponsive
to non-steroidal anti-inflammatory drugs. There remain several unresolved issues about the long-term safety and
quality of life outcomes of biologic treatment in axial spondyloarthropathy. Long-term “real-world” surveillance
data are required to complement data from randomised controlled trials.
Methods/Design: We are conducting a UK-wide prospective cohort study of patients with axial spondyloarthropathy
who are naïve to biologic therapy at the time of recruitment. Those about to commence anti-tumour necrosis factor
biologic therapy will enter a “biologic” sub-cohort with other patients assigned to a “non-biologic” sub-cohort. The
primary objective is to determine whether the use of biologic therapy is associated with an increased risk of serious
infection, while secondary objectives are to assess differences in malignancy, serious comorbidity, all-cause mortality
but also assess impact on specific clinical domains (physical health, mental health and quality of life) including work
outcomes between biologic and non-biologic patient cohorts. Patients will be followed-up for up to 5 years. Data are
obtained at baseline and at standard clinical follow-up visits – at 3, 6 and 12 months and then annually for the biologic
cohort and annually for the non-biologic cohort. This study will also collect biological samples for genetic analysis.
Discussion: Although biologic therapy is widely used for ankylosing spondylitis patients who are unresponsive to
non-steroidal anti-inflammatory drugs, the majority of the available safety information comes from rheumatoid arthritis,
where increased infection risk has consistently been shown. However, given the typical demographic differences
between rheumatoid arthritis and axial spondyloarthropathy patients, it is important to develop an epidemiologically
rigorous cohort of patients receiving biologic therapy to effectively evaluate outcomes with regard not only to safety
but also to quantify benefits across clinical, psychosocial and work outcomes.
Clinical trial registration: This is an observational cohort study and clinical trial registration was not required or
obtained
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Background
Axial spondyloarthritis (axSpA) is a chronic inflammatory
condition that principally affects the spine and sacroiliac
joints but is also associated with peripheral arthritis plus
various extra-articular features such as enthesitis, iritis, in-
flammatory bowel disease and psoriasis. There are two
sub-groups – radiographic axSpA, also known as ankylos-
ing spondylitis (AS), and non-radiographic axSpA – which
have been shown to have similar clinical manifestations
and disease activity measures [1]. AxSpA typically has its
onset early in adulthood [2] and can have a significant im-
pact on aspects of quality of life including disability and
work status [3]. Until recently, treatment has largely been
limited to non-steroidal anti-inflammatory drugs (NSAIDs)
and physiotherapy, while disease-modifying antirheumatic
drugs (DMARDs), though effective in other inflammatory
arthritides, have shown little efficacy in axSpA. The intro-
duction of anti-tumour necrosis factor (anti-TNF) biologic
therapies has been associated with significantly improved
outcomes, including improvements in pain, stiffness and
fatigue [4, 5]. Anti-TNF therapy was initially recommended
in the United Kingdom (UK) for patients with radiographic
axSpA who were unresponsive to NSAIDs and who met
specific disease severity criteria [6] and the extension of
this indication to non-radiographic axSpA is being con-
sidered [7].
Research has highlighted the importance of genetics in
axSpA, in particular the HLA-B27 allele [2]. However,
many important genetic pathways remain unknown and
their relationships to the development of axSpA uncon-
firmed. Genome-wide genetic association studies are cur-
rently underway in international collaborations to elucidate
these pathways and the roles they play in axSpA pathogen-
esis. Although data from randomised clinical trials (RCTs)
of biologic therapy in axSpA have been highly informative,
there remain a number of unresolved issues, since RCTs
are conducted typically on more highly selected popula-
tions than are representative of routine clinical practice [8].
Pharmacological management in rheumatology, includ-
ing the use of disease-suppressive agents, is associated with
adverse side effects in a proportion of patients. In addition,
longer term complications, such as malignancy, are un-
likely to be detected in the relatively short follow-up period
of RCTs. Immunosuppressive therapy, in particular, is con-
sidered to be a potential risk factor for both malignancy
and life-threatening infection. The use of azathioprine and
cyclophosphamide, for example, is associated with an in-
creased risk of lymphoproliferative malignancies in patients
with rheumatoid diseases [9–11]. Immunosuppressed pa-
tients are also at risk of serious infections such as from
Mycobacterium tuberculosis, Pneumocystis carinii and fun-
gal infections [12].
Informed prescribing of biologic agents requires know-
ledge of the magnitude of risk of such longer-term adverse
events. To date, most of the safety information regarding
anti-TNF therapy has come from rheumatoid arthritis
(RA). It is problematic to extrapolate from one condition
to another: RA patients generally have older age at on-
set than axSpA patients, have a significant burden of
co-morbidity, have a longer history of medication use
and have often received polypharmacy including many
other immunosuppressive drugs such as corticosteroids
[2, 13–15]. In terms of benefit, the impact of biologic
therapy on employment maintenance and long-term
quality of life is of great significance for patients and
real-world data are needed in this respect. Furthermore,
the ability to identify those who are most likely to benefit
from a particular treatment is crucial in delivering cost-
effective care. In order to provide axSpA-specific data on
the long term safety and benefit of biologic therapy, we
are conducting a nationwide prospective cohort study: the
British Society for Rheumatology Biologics Register in An-
kylosing Spondylitis (BSRBR-AS).
Methods/Design
Cohort population
Participants are required to meet the Assessment of Spon-
dyloArthritis international Society (ASAS) criteria for radio-
graphic or non-radiographic axSpA, i.e they must satisfy at
least one of the following: i) the modified New York criteria
for AS [16]; ii) the imaging-based ASAS definition of axSpA
[17]; or iii) the “clinical” ASAS definition of axSpA [17]. At
the time of recruitment they are required to be naïve to
biologic therapy. Individuals starting an “eligible” biologic
therapy comprise the “biologic” cohort and those not start-
ing a biologic therapy join the “non-biologic” cohort. The
eligible drug list currently comprises adalimumab (Humira),
etanercept (Enbrel) and certolizumab pegol (Cimzia). Par-
ticipants must be aged at least 16 years and be willing to
give informed consent for follow-up including access to
medical records. Study exclusion criteria are: i) otherwise
eligible patients who are starting a biologic therapy not on
the eligible drug list and ii) inability to communicate in
English. However, once recruited to the study, participants
are eligible to remain in the study irrespective of the sub-
sequent pharmacological or non-pharmacological man-
agement of their condition. Recruitment can take place
through participating National Health Service (NHS) hos-
pitals across the UK.
Study procedures
Patients are informed about BSRBR-AS prior to their
clinic appointment by means of a letter from their con-
sultant rheumatologist and provided with an information
sheet. When patients attend their routine clinic appoint-
ment, they are asked whether they would like to take part
in the study. Consent is taken by the consultant rheuma-
tologist or an appropriately trained member of the site
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research team. In exceptional circumstances, patients may
complete the consent form at home and return it by post.
Patients are ordinarily given at least 24 hours to consider
the Patient Information Sheet and are given the opportun-
ity to ask questions before deciding whether to take part.
All participants are assessed at time of recruitment
(baseline). Patients in the biologic cohort are followed up
at 3, 6 and 12 months after their first dose of biologic
therapy and then annually thereafter. Patients in the non-
biologic cohort are followed up annually from study entry.
This is in line with current UK clinical practice. Each
follow-up involves the collection of clinical and self-report
data as detailed in the section ‘data collection and man-
agement’. Recruitment began in December 2012 and is
currently scheduled to continue until December 2016 and
follow-up will continue to the end of the study period
(currently December 2017), which will provide up to 5
years follow-up for each participant. Assessment of end-
points will be achieved using a combination of physician
and patient report and record linkage to routinely col-
lected health data.
Data collection and management
Clinical data are collected by site clinicians, research nurses
or appropriate delegate at routine clinical appointments.
All data are entered onto the electronic Case Report
Form (eCRF).
The following clinical measures are recorded:
i) Eligibility
ii) Targeted medical history, blood pressure, weight and
height
iii)Active phase reactants (serum C reactive protein
(CRP) or if not available erythrocyte sedimentation
rate (ESR))
iv) Bath Ankylosing Spondylitis Metrology Index
(BASMI) [18]
v) Extra-articular disease features
vi) Pregnancy status of patient or partner
The following self-report measures are collected:
i) Demographic information
ii) Current smoking status and alcohol consumption
iii)Disease activity:
○ Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) [19]
○ Ankylosing Spondylitis Disease Activity Score
(ASDAS) [20]
iv)General measures of AS:
○ Bath Ankylosing Spondylitis Global Score
(BAS-G) [21]
○ Bath Ankylosing Spondylitis Functional Index
(BASFI) [22]
○ Spinal pain visual analogue scale
v) Quality of life:
○ Short Form Health Survey (SF-12) [23]
○ Ankylosing Spondylitis Quality of Life Index
(ASQoL) [24]
○ EuroQoL quality of life measures (EQ-5D-5L and
EQ-VAS) [25]
vi)Other measures including:
○ Chalder fatigue scale [26]
○ Estimation of Sleep Problems [27]
○ Hospital Anxiety and Depression Scale
(HADS) [28]
○Work Productivity and Activity Impairment
Questionnaire: Specific Health Problem
(WPAI: SHP) [29]
○ American College of Rheumatology (ACR)
2011 research criteria for fibromyalgia [30]
Health economics
The health economics analysis will involve the con-
struction of cost and quality of life profiles, based on
EQ-5D-5L and SF-6D (derived from SF-12), for differ-
ent axSpA health states. Costs will include the number
of visits to NHS hospitals for inpatient treatment, day-
case procedures and outpatient services associated with
the condition and related side-effects, recorded from
routine records, valued using standard national sources
such as NHS Reference Costs [31]. Quality of life pro-
files will be estimated from patient self-report, and val-
ued using published UK tariffs. The estimated cost and
quality of life profiles will facilitate the development of eco-
nomic models to assess the cost-effectiveness of biologic
therapy versus non-biologic therapy. A unique feature of
these profiles is that they will be developed from real-life
registry data, and so are more likely to be generalisable to
NHS patients than previously published estimates.
Pharmacovigilance and safety reporting
Clinically confirmed Serious Adverse Events related to
biologic therapies on the eligible drug list are reported
to the relevant pharmaceutical company.
Data analysis and statistics
The study was powered on the primary objective – an
ability to determine a doubling of the risk of serious infec-
tion, i.e infection resulting in hospitalisation or death,
among axSpA patients treated with biologics compared to
the non-biologic cohort. Analysis of this primary endpoint
will be based on comparing the risks of events over time
using Cox proportional hazards regression [32], taking
into account differences between groups such as potential
confounders and disease modifying effects. We will con-
trol for medication switching in the analysis.
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Available data from a meta-analysis of persons enrolled
in trials suggest that the baseline risk of serious infection
is 1.0 per 100 person years in those not randomised to
biologic therapy and that there is an approximate doub-
ling in risk in those receiving biologics [33]. Noting that
adverse events will be more common in routine practice
we have powered the study on a baseline risk of 1.6 cases
per 100 person-years. The power calculation is taken as a
time-to-event analysis and is based on an expected ratio
of 35 biologic patients to every 65 non-biologic patients.
Assuming we wish to be able to detect a Hazard Ratio
(HR) of 2 in the biologic cohort compared to the non-
biologic cohort, i.e. an event rate of 3.2 per 100 person
years, the number of events required for 80 % power is
7.9/(0.65 * 0.35 * log (HR) ^ 2) = 73 events [34], which will
be provided by 1184 and 2216 person-years of observa-
tion in the biologic and non-biologic cohorts respect-
ively. Considering alternative outcomes, not necessarily
related to safety, but also for example treatment re-
sponse, improvements in symptoms and quality of life,
power increases to >95 % for baseline hazards of 3 per
100 person-years in detecting a HR of 2. For baseline
hazards of 10 per 100 person-years the study has 95 %
power to detect a HR of 1.5 while the study has 80 %
power to detect a HR of 1.2 for baseline hazards of 30
per 100 person-years.
Study management and oversight arrangements
The study is co-ordinated by a Study Management Group
consisting of the study investigators. A study co-ordinator
oversees the study and is accountable to the Chief Investi-
gator. An International Advisory Committee advises on
maximising the usefulness of the register for research pur-
poses and on potential collaborations, harmonising oppor-
tunities for data collection with other international studies.
A Data Monitoring Committee is convened by the British
Society for Rheumatology (BSR). The register and data be-
long to the BSR and oversight of this register (and other
registers of the BSR) is undertaken by the BSR Registers
Committee. The committee membership comprises BSR
clinical affairs staff, representatives from BSR members and
from the study investigators.
Research governance
This is an observational cohort study and clinical trial regis-
tration was not required or obtained. The study was peer-
reviewed as part of the process of applying for funds,
competitively, to the BSR. Ethical approval was obtained
from the National Research Ethics Service (NRES) Com-
mittee North East – County Durham and Tees Valley (Re-
search Ethics Committee (REC) reference 11/NE/0374).
Appropriate NHS Research and Development (R&D) ap-
provals are obtained for each site prior to the commence-
ment of study operations in that location. The BSR is the
legal sponsor for the study and delegates certain functions
to the University of Aberdeen. All clinical sites will only
have access to local identifiable patient information. All pa-
tient identifiable study information will be kept confidential
and in compliance with the Data Protection Act (1998).
Dissemination of findings
Dissemination activities in BSRBR-AS will comply with the
BSR Publication Policy. Summaries of results will be made
available for investigators to disseminate within their clin-
ical areas and reports will be produced for the sponsor,
REC and NHS R&D.
Discussion
This study represents one of only a small number of regis-
ters focused on biologic therapy among persons with
axSpA. Such therapies have been shown to be effective in
clinical trials in achieving ASAS 50 % response, in improv-
ing disease activity and function [35]. So why the need for
a register? Firstly, trials are conducted on highly selected
populations [8]. Specifically, trial populations tend to be
younger and have fewer comorbidities than the general
patient population. Trials focus on evaluating efficacy, are
short-term and conducted on relatively small numbers of
patients. In contrast, this register is recruiting patients
with axSpA from centres throughout the UK. These in-
clude some centres with specific expertise in managing
axSpA, but most are local hospitals responsible for man-
aging all rheumatic diseases arising in patients within their
local population. Secondly, eligibility for the register is de-
termined, in terms of disease status, only in relation to
having an eligible diagnosis and in being naïve to biologic
therapy. Thus, patients are not excluded on the basis of
multi-morbidity. Thirdly, patients will be followed up until
the end of study, providing longer-term follow-up. This
will then allow examination of both effectiveness, impact
and safety of these therapies over the medium term.
A novel aspect of the register is the inclusion of persons
who meet only the clinical arm of the ASAS criteria for
axSpA, namely patients who are HLA-B27 positive and
have 2 additional SpA features, but who do not meet the
imaging arm of the ASAS criteria. This will allow the nat-
ural history of axSpA in this sub-group to be determined.
Indeed, the lack of information on the natural history of
non-radiographic axSpA was highlighted by the US Food
and Drug Administration (FDA) in its ruling against wid-
ening indications for anti-TNF therapy beyond radiograph-
ically confirmed axSpA [36]. The current register is the
second under the auspices of the BSR. The first, the British
Society for Rheumatology Biologics Register in Rheuma-
toid Arthritis (BSRBR-RA), was established over 10 years
ago. It uses a similar design as BSRBR-AS and has provided
important evidence on safety of anti-TNF therapy in that
population. For example, the addition of anti-TNF therapy
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to DMARDs did not alter the risk of cancer in RA patients
selected for anti-TNF therapy [37]; a significantly increased
risk of shingles and a doubling in risk of septic arthritis
was observed in those treated with anti-TNF therapy but
an observed increased risk of serious skin and soft tissue
infections was not statistically significant [38, 39] and there
was no excess risk of venous thromboembolism [40]. Using
BSRBR-RA data, Rituximab has been shown to be a more
effective option than a second anti-TNF therapy for pa-
tients who have not responded to an initial anti-TNF
therapy [41].
In 2015, the first ‘biosimilars’ for RA, axSpA and psoriatic
arthritis (PsA) were introduced to the market. A biosimilar
is a biological medicine manufactured to be similar to an
existing ‘reference’ biological medicine, with no meaningful
differences in terms of safety or efficacy. Although pre-
market authorisation includes comparisons against the ref-
erence medicine, this typically involves small scale trials
and they are not undertaken for all indications of the refer-
ence product. There is also little evidence on the safety and
efficacy of switching to biosimilars – and it is thought that
many patients may have their therapy switched in order to
reduce costs to the NHS. The BSR has therefore recom-
mended strongly that all patients starting or switching to
biosimilar agents should be registered with the appropriate
biologics register. The current study will seek to capture
such information on participating patients within BSRBR-
AS, thus expanding the evidence base for these agents [42].
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